The following summary of influenza antiviral treatment recommendations for the 2010-2011 season has been submitted to the Morbidity and Mortality Weekly Report (MMWR) and will appear in that publication at a later date. In the interest of providing this guidance to health care providers as quickly as possible, it is being posted online in the interim.
Note: Recommended antiviral medications (neuraminidase inhibitors) are not licensed for treatment of children <1 year of age (oseltamivir) or aged <7 years (zanamivir). Oseltamivir was used for treatment of 2009 pandemic influenza A (H1N1) virus infection in children <1 year of age under an Emergency Use Authorization (EUA), but this EUA has expired. Limited information on use of oseltamivir for children from birth to 1 year is available (see Table 4).
*While children aged <5 years are considered to be at higher risk for influenza-related complications, the risk is highest among children aged <2 years old.
** The likelihood of influenza virus infection in a patient depends upon the prevalence of influenza activity in the local community, and the patient"e;s signs and symptoms. Information about influenza activity in the U.S. during the influenza season is available at http://www.cdc.gov/flu/weekly/fluactivitysurv.htm. For information on local community influenza activity, clinicians should contact their local and state health departments.
Confirmation of influenza virus infection may be performed by different influenza testing methods. Information on influenza testing is available at: http://www.cdc.gov/flu/professionals/diagnosis/
In areas with limited antiviral medication availability, local public health authorities might provide additional guidance about prioritizing treatment within groups at higher risk for complications. Current CDC guidance on treatment of influenza should be consulted, and updated recommendations from CDC can be found at http://www.cdc.gov/flu/professionals/diagnosis/
Additional guidance on antiviral treatment of influenza